Growth & profitability
- Revenue has grown 319.7% per year over the past 5 years.
- Operating margin has expanded, at 48.2% in the latest year.
Financial health
- Operating income covered interest expense 54× in the latest year.
CRMD Financials Cormedix Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $312M | $163M | 88.5% | 48.2% | 40.2% | 19.7% | $173M | — | $145M |
| 2024 | $43M | -$18M | 92.7% | -51.4% | -21.2% | -15.1% | -$51M | — | $41M |
| 2023 | — | -$46M | — | — | -66.1% | -56.5% | -$39M | — | $44M |
| 2022 | $65408 | -$30M | 94.3% | -46819.9% | -53.9% | -47.9% | -$25M | — | $43M |
| 2021 | $190936 | -$28M | 22.0% | -15417.5% | -44.9% | -40.9% | -$23M | — | $53M |
| 2020 | $239231 | -$22M | 14.4% | -11378.4% | -49.8% | -44.7% | -$22M | — | $42M |
| 2019 | $283266 | -$16M | -31.8% | -7416.3% | -69.5% | -55.8% | -$15M | — | $16M |
| 2018 | $429797 | -$27M | 7.7% | -6250.4% | -543.7% | -142.5% | -$24M | — | $18M |
| 2017 | $329327 | -$33M | 65.1% | -9997.4% | -458.9% | -245.4% | -$29M | — | $10M |
| 2016 | $224105 | -$25M | -63.6% | -11048.8% | -138.3% | -112.5% | -$22M | — | $8M |
| 2015 | $210130 | -$18M | -51.7% | -7925.6% | -53.5% | -49.0% | -$13M | — | $12M |
| 2014 | $189274 | -$20M | -135.5% | -4703.3% | -562.8% | -401.2% | -$6M | — | $4M |
| 2014 | $14204 | -$72M | -1889.8% | -308570.0% | 1932.9% | -738.4% | -$29M | — | $9M |
| 2013 | $2001 | -$9M | -9975.2% | -245646.9% | 227.1% | -307.7% | -$4M | — | $2M |
| 2013 | — | $52M | — | — | -1896.3% | 5009.0% | -$27M | — | $483052 |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $102M | $26M | 75.7% | 42.1% | 5.6% | 2.9% | $86M | — | $257M |
| Mar '26 | $127M | $39M | 82.5% | 50.0% | 8.8% | 4.7% | $42M | — | $178M |
| Dec '25 | — | $14M | — | — | 3.5% | 1.7% | $93M | — | $145M |
| Sep '25 | — | $109M | — | — | 29.0% | 14.5% | $30M | — | $48M |
| Jun '25 | $40M | $20M | 95.3% | 49.2% | 9.0% | 7.8% | $30M | — | $159M |
| Mar '25 | $39M | $21M | 95.9% | 51.5% | 18.0% | 13.8% | $20M | — | $66M |
| Dec '24 | — | $13M | — | — | 15.9% | 11.3% | -$6M | — | $41M |
| Sep '24 | — | -$3M | — | — | -4.7% | -3.6% | -$14M | — | $35M |
| Jun '24 | — | -$14M | — | — | -30.6% | -24.5% | -$14M | — | $29M |
| Mar '24 | — | -$14M | — | — | -24.9% | -21.3% | -$17M | — | $35M |
| Dec '23 | — | -$15M | — | — | -21.0% | -18.0% | -$11M | — | $44M |
| Sep '23 | — | -$10M | — | — | -11.7% | -10.7% | -$9M | — | $53M |
| Jun '23 | — | -$11M | — | — | -23.0% | -19.8% | -$9M | — | $20M |
| Mar '23 | — | -$11M | — | — | -19.6% | -17.8% | -$10M | — | $25M |
| Dec '22 | — | -$8M | — | — | -14.9% | -13.2% | -$6M | — | $43M |
| Sep '22 | — | -$7M | — | — | -12.2% | -11.0% | -$6M | — | $43M |
| Jun '22 | — | -$8M | — | — | -12.3% | -11.2% | -$5M | — | $49M |
| Mar '22 | — | -$7M | — | — | -11.7% | -10.8% | -$7M | — | $45M |
| Dec '21 | — | -$8M | — | — | -12.4% | -11.3% | -$6M | — | $53M |
| Sep '21 | — | -$9M | — | — | -12.4% | -11.4% | -$6M | — | $66M |
Valuation over time
How the market has priced CRMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 5.6× (Dec '25) to 4.0× (Sep '26).
- The price-to-sales ratio has fallen from 4915.6× (Mar '23) to 2.1× (Sep '26).
P/E
P/S
Frequently asked questions
Is CRMD growing its revenue and profit?
Over the past 5 years, Cormedix Inc.'s revenue has grown 319.7% per year. These are computed facts, not advice.
How much debt does CRMD have?
As of FY2025, Cormedix Inc. reported — of total debt against $145M of cash; operating income covered interest expense 54×.
What is CRMD's profit margin?
In FY2025, gross margin was 88.5%, operating margin 48.2%, and net margin 52.3%.
What is CRMD's P/E ratio?
As of Sep '26, Cormedix Inc. traded at a price-to-earnings ratio of about 4.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.